Skip to navigation Skip to content

Clinical Trial: Siponimod in Advancing Relapsing MS

Share

Details
Type of MS: RRMS
Treatment mode of action: To test safety and tolerability
Number of Subjects: 6
Medication: Siponimod
Location: Kansas|Missouri
Institutions: Rowe Neurology Institute/
MidAmerica Neuroscience Research Foundation, Inc.  
8550 Marshall Drive, Suite 100
Lenexa, KS 66214-9836 Contact Information
Lindsay Kreimendahl
913-827-4242
lkreimendahl@neurokc.com

Funding:

Novartis

Description

The main reason for you to take part in this study is to examine how safe and tolerable Siponimod 2mg is in patients with advancing RMS who are switching from the RMS medicine they are currently taking to Siponimod.

Share


© 2020 The National Multiple Sclerosis Society is a tax exempt 501(c)3 nonprofit organization and our Identification Number (EIN) is 13-5661935.